Drug delivery update: Starpharma reports rapid advancement of drug delivery program
3 July 2012
Melbourne, Australia; Starpharma Holdings Ltd (ASX:SPL;OTCQX: SPHRY) today provided an update on the developments within its substantial drug delivery program.
- Dendrimer-docetaxel program advancing rapidly; clinical trial expected to commence in 2013
- Successful application of dendrimers to a number of important classes of drugs including small molecules, antibodies and proteins
- Analysis shows Starpharma’s dendrimers applicable to more than 50% of top-selling pharmaceuticals - highlighting versatility and potential to develop improved formulations